260 related articles for article (PubMed ID: 9230856)
1. Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus.
Katada N; Hinder RA; Smyrk TC; Hirabayashi N; Perdikis G; Lund RJ; Woodward T; Klingler PJ
Arch Surg; 1997 Jul; 132(7):728-33. PubMed ID: 9230856
[TBL] [Abstract][Full Text] [Related]
2. [Expression of c-myb in reflux esophagitis, Barrett esophagus and esophageal adenocarcinoma].
Ren CR; Dong L; Guo XY
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Dec; 30(12):2693-5. PubMed ID: 21177182
[TBL] [Abstract][Full Text] [Related]
3. Esophageal Helicobacter pylori colonization aggravates esophageal injury caused by reflux.
Chu YX; Wang WH; Dai Y; Teng GG; Wang SJ
World J Gastroenterol; 2014 Nov; 20(42):15715-26. PubMed ID: 25400455
[TBL] [Abstract][Full Text] [Related]
4. Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus.
Soslow RA; Remotti H; Baergen RN; Altorki NK
Mod Pathol; 1999 Mar; 12(3):239-50. PubMed ID: 10102608
[TBL] [Abstract][Full Text] [Related]
5. E-cadherin expression in gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma: an immunohistochemical and immunoblot study.
Swami S; Kumble S; Triadafilopoulos G
Am J Gastroenterol; 1995 Oct; 90(10):1808-13. PubMed ID: 7572899
[TBL] [Abstract][Full Text] [Related]
6. Alterations in manganese superoxide dismutase expression in the progression from reflux esophagitis to esophageal adenocarcinoma.
Li Y; Wo JM; Su RR; Ray MB; Martin RC
Ann Surg Oncol; 2007 Jul; 14(7):2045-55. PubMed ID: 17473952
[TBL] [Abstract][Full Text] [Related]
7. Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in esophageal carcinogenesis.
Herszenyi L; Hritz I; Pregun I; Sipos F; Juhasz M; Molnar B; Tulassay Z
World J Gastroenterol; 2007 Feb; 13(5):676-82. PubMed ID: 17278189
[TBL] [Abstract][Full Text] [Related]
8. Increased p53 expression in the malignant transformation of Barrett's esophagus is accompanied by an upward shift of the proliferative compartment.
Hritz I; Gyorffy H; Molnar B; Lakatos G; Sipos F; Pregun I; Juhasz M; Pronai L; Schaff Z; Tulassay Z; Herszenyi L
Pathol Oncol Res; 2009 Jun; 15(2):183-92. PubMed ID: 18752044
[TBL] [Abstract][Full Text] [Related]
9. Anterior gradient 2 profiling in Barrett columnar epithelia and adenocarcinoma.
Pizzi M; Fassan M; Realdon S; Balistreri M; Battaglia G; Giacometti C; Zaninotto G; Zagonel V; De Boni M; Rugge M
Hum Pathol; 2012 Nov; 43(11):1839-44. PubMed ID: 22521076
[TBL] [Abstract][Full Text] [Related]
10. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
11. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
12. Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus.
Hanas JS; Lerner MR; Lightfoot SA; Raczkowski C; Kastens DJ; Brackett DJ; Postier RG
Cancer; 1999 Sep; 86(5):756-63. PubMed ID: 10463972
[TBL] [Abstract][Full Text] [Related]
13. c-Myc overexpression is strongly associated with metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
Schmidt MK; Meurer L; Volkweis BS; Edelweiss MI; Schirmer CC; Kruel CD; Gurski RR
Dis Esophagus; 2007; 20(3):212-6. PubMed ID: 17509117
[TBL] [Abstract][Full Text] [Related]
14. Expression of acidic fibroblast growth factor in Barrett's esophagus and associated esophageal adenocarcinoma.
Soslow RA; Ying L; Altorki NK
J Thorac Cardiovasc Surg; 1997 Nov; 114(5):838-43. PubMed ID: 9375615
[TBL] [Abstract][Full Text] [Related]
15. Expression of apoptosis-related proteins in Barrett's metaplasia-dysplasia-carcinoma sequence: a switch to a more resistant phenotype.
van der Woude CJ; Jansen PL; Tiebosch AT; Beuving A; Homan M; Kleibeuker JH; Moshage H
Hum Pathol; 2002 Jul; 33(7):686-92. PubMed ID: 12196918
[TBL] [Abstract][Full Text] [Related]
16. Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett's esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies.
Lewis CJ; Thrumurthy SG; Pritchard S; Armstrong G; Attwood SE
Surg Endosc; 2011 Aug; 25(8):2564-9. PubMed ID: 21359892
[TBL] [Abstract][Full Text] [Related]
17. CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target.
Hansel DE; Dhara S; Huang RC; Ashfaq R; Deasel M; Shimada Y; Bernstein HS; Harmon J; Brock M; Forastiere A; Washington MK; Maitra A; Montgomery E
Am J Surg Pathol; 2005 Mar; 29(3):390-9. PubMed ID: 15725809
[TBL] [Abstract][Full Text] [Related]
18. Toll-like Receptor 2 Signalling and the Lysosomal Machinery in Barrett's Esophagus.
Verbeek RE; Siersema PD; Vleggaar FP; Ten Kate FJ; Posthuma G; Souza RF; de Haan J; van Baal JW
J Gastrointestin Liver Dis; 2016 Sep; 25(3):273-82. PubMed ID: 27689189
[TBL] [Abstract][Full Text] [Related]
19. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia.
Anandasabapathy S; Jhamb J; Davila M; Wei C; Morris J; Bresalier R
Cancer; 2007 Feb; 109(4):668-74. PubMed ID: 17211862
[TBL] [Abstract][Full Text] [Related]
20. Expression of cyclin B1 in the metaplasia-dysplasia-carcinoma sequence of Barrett esophagus.
Geddert H; Heep HJ; Gabbert HE; Sarbia M
Cancer; 2002 Jan; 94(1):212-8. PubMed ID: 11815979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
